LASIK outcomes comparing vector planning to manifest refraction for the treatment of myopic astigmatism

Session Details

Session Title: Presented Poster Session: Refractive Surgery New Techniques/Instrumentation/Devices I

Venue: Poster Village: Pod 2

First Author: : N.Alpins AUSTRALIA

Co Author(s): :    M. Arbelaez   S. Arba-Mosquera                    

Abstract Details

Purpose:

To investigate refractive astigmatism outcomes including the ocular residual astigmatism (ORA) using excimer laser treatments based on vector planning compared to manifest refractive cylinder alone.

Setting:

NewVision Clinics, 7 Chesterville Road, Cheltenham VIC Australia, 3192

Methods:

A prospective study was performed on 160 consecutive eyes undergoing refractive laser surgery for myopic astigmatism on the Schwind Amaris Total-Tech laser with Ziemer LDV femtosecond laser for flap creation. The first 80 eyes were treated using Vector Planning, which incorporates the corneal astigmatism as well as the manifest refractive astigmatism into the treatment plan with 60% emphasis placed on the correction of refractive cylinder and 40% emphasis based on the correction of corneal astigmatism. The last 80 eyes were treated using the manifest refraction alone. Inclusion criteria were based on an ocular residual astigmatism (ORA) of > 0.75D.

Results:

6 months postoperatively, the Vector Planning group had 97% of eyes < 0.25D of refractive cylinder, the manifest refraction group had 92% of eyes. 96% of eyes in vector planning group versus 93% of eyes in manifest refraction group had UDVA of 20/20 or better. 90% of eyes in vector planning group had postop spherical equivalent within 0.13D compared with 68% for manifest refraction group and 75% of eyes in vector planning group had corneal astigmatism of < 0.75D compared with 34% of eyes in the manifest refraction group.

Conclusions:

Excimer laser treatments using vector planning resulted in less corneal astigmatism, less refractive cylinder and total astigmatism, and better unaided visual acuity postoperatively than treatments using manifest refractive cylinder treatment parameters alone.

Financial Disclosure:

gains financially from product or procedure presented